Insider Analysis From Heller Ehrman LLP: Understanding How the FCPA Affects Pharma Interests in China (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
By Michael Phillips, Heller Ehrman, Hong Kon
You may also be interested in...
Insider Analysis From Heller Ehrman LLP: Understanding How the FCPA Affects Pharma Interests in China (Part 1 of 2)
By Michael Phillips, Heller Ehrman, Hong Kon
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).